Circulating Tumor Cell Device Gets Safer FDA Classification
Published Date: 5/6/2026
Rule
Summary
The FDA is officially classifying the circulating tumor cell enrichment device as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to innovative cancer-fighting tools faster and keeps the device safe and effective. The new rules take effect May 6, 2026, and could save time and money for makers and users of this device.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Easier Path for Future Devices
FDA states that once this device type is classified into Class II via the De Novo process, it can serve as a predicate for future devices. That means other device sponsors may be able to use the less-burdensome 510(k) process to bring substantially equivalent devices to market instead of submitting a De Novo request or a premarket approval application.
Device Reclassified to Class II
FDA has classified the circulating tumor cell enrichment device as Class II (special controls). This order is effective May 6, 2026 (and the classification was applicable May 24, 2022). FDA says this classification will provide reasonable assurance of safety and effectiveness and will enhance patients' access to innovative devices by reducing regulatory burdens.
Manufacturers Must Meet Special Controls
Circulating tumor cell enrichment devices remain subject to premarket notification under section 510(k) and must meet the special controls codified at 21 CFR 866.6110. Manufacturers must provide specified labeling (including intended use, limitations, and troubleshooting) and design verification and validation data, including analytical and clinical study documentation demonstrating performance, detection limits, precision, recovery, and stability.
Labeling Limits Use; Not Diagnostic
The device's labeling must prominently state that the standalone device is intended only to enrich circulating tumor cells (CTCs) from peripheral blood of previously diagnosed cancer patients and is not intended for diagnostic, prognostic, or monitoring use. Labeling must also state that results do not provide information about a patient's current health and that downstream assays need separate validation.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2026-08811, Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Preserve and Stabilize Relative Abundances of Microbial Nucleic Acids in Clinical Samples
The FDA is officially putting a special label (Class II) on devices that keep tiny germs’ DNA stable in medical samples. This change makes sure these devices are safe and work well, while also making it easier and faster for new, helpful devices to reach patients. The new rules started May 6, 2026, and could save time and money for companies making these devices.
Next: 2026-08813, Medical Devices; Ophthalmic Devices; Classification of the Corneal Storage Medium With Preservatives Including Antifungals
The FDA is officially putting corneal storage fluids with preservatives and antifungals into a safer, easier-to-manage category called Class II. This change helps make sure these eye care products are safe and effective while speeding up access to new, helpful devices. Starting May 6, 2026, companies will follow these new rules, which could save time and money by cutting down on red tape.